Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+lymphomas.

被引：1
|
作者：
Schuster, Stephen J.
Svoboda, Jakub
Nasta, Sunita
Porter, David L.
Mato, Anthony
Shah, Gaurav D.
Landsburg, Daniel Jeffrey
Chong, Elise A.
Lacey, Simon F.
Melenhorst, Jan J.
Chew, Anne
Hasskarl, Jens
Shah, Nirav Niranjan
Wasik, Mariusz A.
Marcucci, Katherine
Zheng, Zhaohui
Levine, Bruce
June, Carl H.
机构：
[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA
[3] Univ Penn Hlth Syst, Philadelphia, PA USA
[4] Novartis Pharmaceut, Florham Pk, NJ USA
[5] Novartis, Basel, Switzerland
[6] Univ Penn, Translat Res Program, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8516
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Donor-derived CD19 chimeric antigen receptor T cells
    Singh, Nathan
    Barrett, David M.
    CURRENT OPINION IN HEMATOLOGY, 2015, 22 (06) : 503 - 508
  • [42] CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas
    Onea, Alexandra S.
    Jazirehi, Ali R.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (02): : 403 - 424
  • [43] CHIMERIC ANTIGEN RECEPTOR (CAR)-MODIFIED T CELLS TARGETING CD19 INDUCE SUSTAINED REMISSIONS IN CHILDREN AND YOUNG ADULTS WITH RELAPSED/REFRACTORY ALL
    Maude, S.
    Shaw, P.
    Aplenc, R.
    Barrett, D.
    Barker, C.
    Callahan, C.
    Grupp, C.
    Lacey, S.
    Levine, B.
    Melenhorst, J.
    Motley, L.
    Rheingold, S.
    Teachey, D.
    June, C.
    Grupp, S.
    HAEMATOLOGICA, 2015, 100 : 6 - 6
  • [44] Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
    Ying, Zhitao
    He, Ting
    Wang, Xiaopei
    Zheng, Wen
    Lin, Ningjing
    Tu, Meifeng
    Xie, Yan
    Ping, Lingyan
    Zhang, Chen
    Liu, Weiping
    Deng, Lijuan
    Wu, Meng
    Feng, Feier
    Leng, Xin
    Du, Tingting
    Qi, Feifei
    Hu, Xuelian
    Ding, Yanping
    Lu, Xin-an
    Song, Yuqin
    Zhu, Jun
    BMC CANCER, 2021, 21 (01)
  • [45] CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T-cells for the treatment of relapsed or refractory B-cell lymphomas.
    Ghafouri, Sanaz Noelle
    Walthers, Christopher
    Roshandell, Mobina
    Ji, Brenda
    Trent, Jacqueline
    Chen, Jia Ming
    Naparstek, Jacob
    Harris, Caitlin
    Schweppe, Thomas
    Nawaly, Karla K.
    Mead, Monica
    de Vos, Sven
    Young, Patricia
    Oliai, Caspian
    Schiller, Gary
    Timmerman, John M.
    Chen, Yvonne Y.
    Larson, Sarah
    CANCER RESEARCH, 2021, 81 (13)
  • [46] Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
    Zhitao Ying
    Ting He
    Xiaopei Wang
    Wen Zheng
    Ningjing Lin
    Meifeng Tu
    Yan Xie
    Lingyan Ping
    Chen Zhang
    Weiping Liu
    Lijuan Deng
    Meng Wu
    Feier Feng
    Xin Leng
    Tingting Du
    Feifei Qi
    Xuelian Hu
    Yanping Ding
    Xin-an Lu
    Yuqin Song
    Jun Zhu
    BMC Cancer, 21
  • [47] Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice
    Wen, Hairuo
    Qu, Zhe
    Yan, Yujing
    Pu, Chengfei
    Wang, Chao
    Jiang, Hua
    Hou, Tiantian
    Huo, Yan
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (23)
  • [48] How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells
    Nagler, Arnon
    Perriello, Vincenzo Maria
    Falini, Lorenza
    Falini, Brunangelo
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (03) : 396 - 410
  • [49] Clonal Evolution of a Mutation in PTPRA As a Potential Cause for Resistance Against Anti-CD19 Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy with CTL019 in DLBCL Patients
    Balke-Want, Hyatt
    Godel, Philipp
    Abedpour, Nima
    Peifer, Martin
    Borchmann, Peter
    BLOOD, 2018, 132
  • [50] Phase 1 trial of CD19/CD20 bispecific chimeric antigen receptor-engineered naive/memory T cells for relapsed or refractory non-Hodgkin lymphoma
    Puliafito, Benjamin R.
    Walthers, Christopher
    Ji, Brenda
    Ghafouri, Sanaz N.
    Naparstek, Jacob
    Trent, Jacqueline
    Chen, Jia M.
    Roshandell, Mobina
    Harris, Caitlin
    Khericha, Mobina
    Schweppe, Thomas
    Berent-Maoz, Beata
    Gosliner, Stanley B.
    Almaktari, Amr
    Ceja, Melanie Ayala
    Allen-Auerbach, Martin S.
    Said, Jonathan
    Nawaly, Karla
    Mead, Monica
    de Vos, Sven
    Young, Patricia A.
    Oliai, Caspian
    Schiller, Gary J.
    Timmerman, John M.
    Ribas, Antoni
    Chen, Yvonne Y.
    Larson, Sarah M.
    CANCER RESEARCH, 2023, 83 (08)
12345